1. Home
  2. JNVR vs BCDA Comparison

JNVR vs BCDA Comparison

Compare JNVR & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JNVR
  • BCDA
  • Stock Information
  • Founded
  • JNVR 2018
  • BCDA N/A
  • Country
  • JNVR United States
  • BCDA United States
  • Employees
  • JNVR N/A
  • BCDA N/A
  • Industry
  • JNVR Finance: Consumer Services
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • JNVR Finance
  • BCDA Health Care
  • Exchange
  • JNVR Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • JNVR 7.3M
  • BCDA 7.9M
  • IPO Year
  • JNVR 2023
  • BCDA N/A
  • Fundamental
  • Price
  • JNVR $5.29
  • BCDA $2.32
  • Analyst Decision
  • JNVR
  • BCDA Strong Buy
  • Analyst Count
  • JNVR 0
  • BCDA 1
  • Target Price
  • JNVR N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • JNVR 17.8K
  • BCDA 54.1K
  • Earning Date
  • JNVR 03-27-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • JNVR N/A
  • BCDA N/A
  • EPS Growth
  • JNVR N/A
  • BCDA N/A
  • EPS
  • JNVR N/A
  • BCDA N/A
  • Revenue
  • JNVR $1,820,969.00
  • BCDA $71,000.00
  • Revenue This Year
  • JNVR N/A
  • BCDA N/A
  • Revenue Next Year
  • JNVR N/A
  • BCDA N/A
  • P/E Ratio
  • JNVR N/A
  • BCDA N/A
  • Revenue Growth
  • JNVR N/A
  • BCDA N/A
  • 52 Week Low
  • JNVR $3.37
  • BCDA $0.32
  • 52 Week High
  • JNVR $11.84
  • BCDA $5.70
  • Technical
  • Relative Strength Index (RSI)
  • JNVR 52.17
  • BCDA 49.50
  • Support Level
  • JNVR $5.29
  • BCDA $2.12
  • Resistance Level
  • JNVR $5.61
  • BCDA $2.73
  • Average True Range (ATR)
  • JNVR 0.51
  • BCDA 0.23
  • MACD
  • JNVR -0.02
  • BCDA 0.01
  • Stochastic Oscillator
  • JNVR 33.48
  • BCDA 35.82

About JNVR Janover Inc.

Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: